CN110391028A - 用于生产个性化定制药物产品的系统和方法 - Google Patents
用于生产个性化定制药物产品的系统和方法 Download PDFInfo
- Publication number
- CN110391028A CN110391028A CN201910480856.6A CN201910480856A CN110391028A CN 110391028 A CN110391028 A CN 110391028A CN 201910480856 A CN201910480856 A CN 201910480856A CN 110391028 A CN110391028 A CN 110391028A
- Authority
- CN
- China
- Prior art keywords
- drug
- information
- patient
- digestible
- optimal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 49
- 229940127557 pharmaceutical product Drugs 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 493
- 229940079593 drug Drugs 0.000 claims abstract description 457
- 238000000034 method Methods 0.000 claims abstract description 44
- 229940000425 combination drug Drugs 0.000 claims abstract description 43
- 229940126534 drug product Drugs 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 38
- 238000002483 medication Methods 0.000 claims description 36
- 238000005259 measurement Methods 0.000 claims description 22
- 230000002974 pharmacogenomic effect Effects 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000000090 biomarker Substances 0.000 claims description 14
- 238000004891 communication Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 12
- 230000003907 kidney function Effects 0.000 claims description 10
- 230000007958 sleep Effects 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 230000008406 drug-drug interaction Effects 0.000 claims description 9
- 230000036961 partial effect Effects 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 5
- 230000003542 behavioural effect Effects 0.000 claims description 5
- 230000007613 environmental effect Effects 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 208000000412 Avitaminosis Diseases 0.000 claims description 4
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 4
- 206010073306 Exposure to radiation Diseases 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000001351 cycling effect Effects 0.000 claims description 3
- 231100000573 exposure to toxins Toxicity 0.000 claims description 3
- 238000007639 printing Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000007905 drug manufacturing Methods 0.000 claims description 2
- 206010021135 Hypovitaminosis Diseases 0.000 claims 2
- 239000011573 trace mineral Substances 0.000 claims 2
- 235000013619 trace mineral Nutrition 0.000 claims 2
- 208000030401 vitamin deficiency disease Diseases 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 25
- 230000003902 lesion Effects 0.000 abstract description 4
- 239000000306 component Substances 0.000 description 23
- 239000003937 drug carrier Substances 0.000 description 22
- 239000000890 drug combination Substances 0.000 description 21
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 18
- 229960001138 acetylsalicylic acid Drugs 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 17
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 16
- 239000002876 beta blocker Substances 0.000 description 16
- 229940097320 beta blocking agent Drugs 0.000 description 16
- 208000010125 myocardial infarction Diseases 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 9
- 229960003009 clopidogrel Drugs 0.000 description 9
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000006187 pill Substances 0.000 description 7
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 6
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000021642 Muscular disease Diseases 0.000 description 5
- 201000009623 Myopathy Diseases 0.000 description 5
- 238000013473 artificial intelligence Methods 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 4
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000003066 decision tree Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011369 optimal treatment Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 229960002274 atenolol Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940072645 coumadin Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 3
- 229960002582 perindopril Drugs 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 239000000955 prescription drug Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 206010057362 Underdose Diseases 0.000 description 2
- 206010047627 Vitamin deficiencies Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 235000021384 green leafy vegetables Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960004197 prasugrel Drugs 0.000 description 2
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- XJBQVBPGIOOPMP-HNNXBMFYSA-N (3s)-3-[[6-[[[3-(methylsulfonylcarbamoyl)phenyl]sulfonylamino]methyl]pyridine-3-carbonyl]amino]-4-oxobutanoic acid Chemical compound CS(=O)(=O)NC(=O)C1=CC=CC(S(=O)(=O)NCC=2N=CC(=CC=2)C(=O)N[C@@H](CC(O)=O)C=O)=C1 XJBQVBPGIOOPMP-HNNXBMFYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- SIRDBTDSADKLJV-SFHVURJKSA-N 5-[[5-[[(2s)-3-carboxy-1-(7-methoxy-1,3-benzoxazol-2-yl)-1-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]-2-hydroxybenzoic acid Chemical compound N([C@@H](CC(O)=O)C(=O)C1=NC=2C=CC=C(C=2O1)OC)C(=O)C(C=N1)=CC=C1CNS(=O)(=O)C1=CC=C(O)C(C(O)=O)=C1 SIRDBTDSADKLJV-SFHVURJKSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000027036 Hippa Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 241000198620 Infundibulicybe gibba Species 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108091006731 SLCO1B1 Proteins 0.000 description 1
- 101150018278 SLCO1B1 gene Proteins 0.000 description 1
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 229940085754 ace inhibitors and diuretics Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 101150091521 lpa gene Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
- B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
- B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
- B65D51/2814—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it
- B65D51/2828—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being a film or a foil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
- A61J3/074—Filling capsules; Related operations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/30—Compliance analysis for taking medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/60—General identification or selection means using magnetic or electronic identifications, e.g. chips, RFID, electronic tags
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6054—Magnetic identification systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Primary Health Care (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Mechanical Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Business, Economics & Management (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Tourism & Hospitality (AREA)
- Child & Adolescent Psychology (AREA)
- Economics (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Strategic Management (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40150310P | 2010-08-13 | 2010-08-13 | |
| US61/401,503 | 2010-08-13 | ||
| CN2011800491775A CN103250176A (zh) | 2010-08-13 | 2011-08-15 | 用于生产个性化定制药物产品的系统和方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800491775A Division CN103250176A (zh) | 2010-08-13 | 2011-08-15 | 用于生产个性化定制药物产品的系统和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110391028A true CN110391028A (zh) | 2019-10-29 |
Family
ID=45565458
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910480856.6A Pending CN110391028A (zh) | 2010-08-13 | 2011-08-15 | 用于生产个性化定制药物产品的系统和方法 |
| CN2011800491775A Pending CN103250176A (zh) | 2010-08-13 | 2011-08-15 | 用于生产个性化定制药物产品的系统和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800491775A Pending CN103250176A (zh) | 2010-08-13 | 2011-08-15 | 用于生产个性化定制药物产品的系统和方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10189616B2 (enExample) |
| EP (1) | EP2603900B1 (enExample) |
| JP (3) | JP2013535756A (enExample) |
| CN (2) | CN110391028A (enExample) |
| AU (1) | AU2011289158B2 (enExample) |
| BR (1) | BR112013003331A2 (enExample) |
| CA (1) | CA2807949C (enExample) |
| IN (1) | IN2013MN00290A (enExample) |
| MX (1) | MX2013001744A (enExample) |
| WO (1) | WO2012021899A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111326228A (zh) * | 2020-02-19 | 2020-06-23 | 清华大学 | 一种用于确定药物颗粒下呼吸道给药剂量的方法及系统 |
| CN114582457A (zh) * | 2020-11-30 | 2022-06-03 | 国际商业机器公司 | 时间控制的药物 |
| CN114981191A (zh) * | 2019-11-20 | 2022-08-30 | 雀巢产品有限公司 | 用于管理食物过敏口服免疫疗法药物的分发和治疗的方法和系统 |
| TWI812056B (zh) * | 2022-03-10 | 2023-08-11 | 宏碁股份有限公司 | 檢查藥物相互作用的方法和電子裝置 |
Families Citing this family (189)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8316798B2 (en) * | 2005-01-21 | 2012-11-27 | Masami Ito | Individually mixed pet feed supply system |
| ES3004613T3 (en) | 2009-07-29 | 2025-03-12 | Icu Medical Inc | Fluid transfer devices |
| EP2603900B1 (en) | 2010-08-13 | 2024-04-24 | Intellimedicine, Inc. | System and methods for the production of personalized drug products |
| CN103249340B (zh) * | 2010-11-05 | 2017-02-15 | 赛诺亚科技有限公司 | 具有用于吸收物质并防止物质渗漏的海绵的美容涂抹器 |
| EP2654658A4 (en) * | 2010-12-23 | 2016-04-06 | Tailorpill Technologies Llc | SYSTEM AND METHOD FOR PERSONALIZED PILLAR CONNECTIONS |
| US9449296B2 (en) | 2011-08-02 | 2016-09-20 | Kit Check, Inc. | Management of pharmacy kits using multiple acceptance criteria for pharmacy kit segments |
| US8990099B2 (en) | 2011-08-02 | 2015-03-24 | Kit Check, Inc. | Management of pharmacy kits |
| US20130054011A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Social Network Selection System and Method for Ingestible Material Preparation System and Method |
| US9785985B2 (en) | 2011-08-26 | 2017-10-10 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
| US10121218B2 (en) | 2012-06-12 | 2018-11-06 | Elwha Llc | Substrate structure injection treatment system and method for ingestible product system and method |
| US9997006B2 (en) | 2011-08-26 | 2018-06-12 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
| US10115093B2 (en) | 2011-08-26 | 2018-10-30 | Elwha Llc | Food printing goal implementation substrate structure ingestible material preparation system and method |
| US9922576B2 (en) | 2011-08-26 | 2018-03-20 | Elwha Llc | Ingestion intelligence acquisition system and method for ingestible material preparation system and method |
| US9111256B2 (en) | 2011-08-26 | 2015-08-18 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
| US8892249B2 (en) | 2011-08-26 | 2014-11-18 | Elwha Llc | Substance control system and method for dispensing systems |
| US9947167B2 (en) | 2011-08-26 | 2018-04-17 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
| US20130054695A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Social network reporting system and method for ingestible material preparation system and method |
| US20130330447A1 (en) | 2012-06-12 | 2013-12-12 | Elwha LLC, a limited liability company of the State of Delaware | Substrate Structure Deposition Treatment System And Method For Ingestible Product System and Method |
| US10192037B2 (en) | 2011-08-26 | 2019-01-29 | Elwah LLC | Reporting system and method for ingestible product preparation system and method |
| US20130054255A1 (en) | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Controlled substance authorization and method for ingestible product preparation system and method |
| US8989895B2 (en) | 2011-08-26 | 2015-03-24 | Elwha, Llc | Substance control system and method for dispensing systems |
| US9619958B2 (en) | 2012-06-12 | 2017-04-11 | Elwha Llc | Substrate structure duct treatment system and method for ingestible product system and method |
| US10239256B2 (en) | 2012-06-12 | 2019-03-26 | Elwha Llc | Food printing additive layering substrate structure ingestible material preparation system and method |
| US9240028B2 (en) | 2011-08-26 | 2016-01-19 | Elwha Llc | Reporting system and method for ingestible product preparation system and method |
| US20130054010A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Social network reporting system and method for ingestible material preparation system and method |
| US20150287123A1 (en) * | 2011-08-26 | 2015-10-08 | Elwha Llc | 3d food printing shopping history substrate structure ingestible material preparation system and method |
| US10026336B2 (en) | 2011-08-26 | 2018-07-17 | Elwha Llc | Refuse intelligence acquisition system and method for ingestible product preparation system and method |
| US20130054387A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Stock Supply Based Modifiable Selection System and Method for Ingestible Material Preparation System and Method |
| US9037478B2 (en) | 2011-08-26 | 2015-05-19 | Elwha Llc | Substance allocation system and method for ingestible product preparation system and method |
| US10265245B2 (en) | 2011-08-27 | 2019-04-23 | Daniel L. Kraft | Portable drug dispenser |
| EP2758014A4 (en) * | 2011-09-19 | 2015-09-02 | Daniel L Kraft | EYE DROPS DONORS |
| AU2012324021A1 (en) | 2011-12-22 | 2013-07-11 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
| US20140379369A1 (en) * | 2012-01-04 | 2014-12-25 | Draeger Medical Systems, Inc. | Patient Identification and Monitoring System |
| WO2013141386A1 (ja) * | 2012-03-23 | 2013-09-26 | 独立行政法人科学技術振興機構 | パーソナルゲノム情報環境提供装置、パーソナルゲノム情報環境提供方法、および、プログラム |
| US20140089009A1 (en) * | 2012-09-27 | 2014-03-27 | Wobblebase, Inc. | Method for Personal Genome Data Management |
| US9511945B2 (en) | 2012-10-12 | 2016-12-06 | Aesynt Incorporated | Apparatuses, systems, and methods for transporting medications from a central pharmacy to a patient in a healthcare facility |
| WO2014059310A2 (en) * | 2012-10-12 | 2014-04-17 | Mckesson Automation Inc. | Apparatuses, systems, and methods for delivering medications from a central pharmacy to a patient in a healthcare facility |
| US9150119B2 (en) | 2013-03-15 | 2015-10-06 | Aesynt Incorporated | Apparatuses, systems, and methods for anticipating and delivering medications from a central pharmacy to a patient using a track based transport system |
| KR101419753B1 (ko) * | 2012-10-16 | 2014-07-17 | 안형준 | 개인 단일 염기 다형성에 기반한 개인별 부작용 최소화 약물 검색 시스템 및 그 방법 |
| KR20150079770A (ko) * | 2012-10-23 | 2015-07-08 | 테라노스, 인코포레이티드 | 보조 의료 및 관련된 라이프 스타일 의사 결정 |
| KR101327533B1 (ko) * | 2012-12-11 | 2013-11-08 | 사회복지법인 삼성생명공익재단 | 환자 맞춤형 항암제 선별용 시스템 |
| US20140229191A1 (en) * | 2013-02-04 | 2014-08-14 | Sano Informed Prescribing, Llc | Prescription decision support system and method using comprehensive multiplex drug monitoring |
| US10262112B2 (en) | 2013-02-04 | 2019-04-16 | Precera Bioscience, Inc. | Prescription decision support system and method using comprehensive multiplex drug monitoring |
| US20140244556A1 (en) * | 2013-02-27 | 2014-08-28 | Abdul Saleh | Methods for and apparatus generating automated pharmaco genetics correlation |
| EP3300015B1 (en) | 2013-03-12 | 2019-08-14 | Panacea Biomatx Inc. | System for making customized formulations for individuals |
| WO2014145074A1 (en) | 2013-03-15 | 2014-09-18 | Makefield Llc | Functional desiccants |
| CN104077466A (zh) * | 2013-03-31 | 2014-10-01 | 邓培友 | 饮食剂量傻瓜计算法 |
| MX361092B (es) | 2013-05-23 | 2018-11-26 | Iphenotype Llc | Base de datos de búsqueda social integrada fenotípica y método. |
| US10777313B2 (en) | 2013-06-13 | 2020-09-15 | Carefusion 303, Inc. | Analytics regarding ventilated patients |
| TW201504985A (zh) * | 2013-07-18 | 2015-02-01 | Hon Hai Prec Ind Co Ltd | 利用雲端伺服器實現用藥指導之方法及系統 |
| DE102013015164B4 (de) | 2013-09-11 | 2017-07-06 | Sartorius Stedim Biotech Gmbh | Verfahren zur Gestaltung eines Reinraums und Verfahren für die Herstellung von pharmazeutischen Produkten mit einem Navigationssystem |
| JP6221654B2 (ja) * | 2013-11-08 | 2017-11-01 | 富士通株式会社 | 副作用出力プログラム、副作用出力方法及び副作用出力装置 |
| US20150149539A1 (en) * | 2013-11-22 | 2015-05-28 | Adobe Systems Incorporated | Trending Data Demographics |
| JP6259113B2 (ja) | 2013-11-25 | 2018-01-10 | アイシーユー・メディカル・インコーポレーテッド | 点滴バッグに治療用流体を充填するための方法およびシステム |
| MX2016006549A (es) * | 2013-12-06 | 2016-09-06 | Carefusion 303 Inc | Sistema de analisis para el cuidado de un paciente. |
| US9171280B2 (en) | 2013-12-08 | 2015-10-27 | Kit Check, Inc. | Medication tracking |
| US10431329B2 (en) * | 2014-02-27 | 2019-10-01 | Steven L. Kagen | Real-time symptom analysis system and method |
| US20150254426A1 (en) * | 2014-03-10 | 2015-09-10 | Yariv Glazer | Method and Apparatus for Preparing Medications for Administration to Subjects |
| US20150269345A1 (en) * | 2014-03-19 | 2015-09-24 | International Business Machines Corporation | Environmental risk factor relevancy |
| DE102014105058A1 (de) * | 2014-04-09 | 2015-10-15 | Stephanie Ittstein | Vorrichtung zu einer Herstellung und/oder zu einer Verabreichung |
| AU2015263371B2 (en) | 2014-05-21 | 2018-08-23 | Société des Produits Nestlé S.A. | System, process and device for producing a nutritional composition with personalized nutrient content |
| JP6368782B2 (ja) | 2014-05-30 | 2018-08-01 | 株式会社日立製作所 | 医薬品製造支援システム及び医薬品製造支援方法 |
| US20170132391A1 (en) * | 2014-06-13 | 2017-05-11 | Microdose Therapeutx, Inc | Medical device communication |
| US20160039553A1 (en) | 2014-08-05 | 2016-02-11 | Makefield Llc | Dispensable unit identification |
| EP3178028A4 (en) * | 2014-08-06 | 2018-04-11 | Healthbeacon Inc. | Medication dispensing phone case |
| KR20250005500A (ko) * | 2014-08-22 | 2025-01-09 | 가부시키가이샤 유야마 세이사쿠쇼 | 약제 분류 장치 |
| US10172996B2 (en) * | 2014-08-22 | 2019-01-08 | Fenwal, Inc. | Medical solution authentication |
| CN112985567B (zh) * | 2014-09-08 | 2023-07-18 | 贝克顿·迪金森公司 | 用于药物配制的增强台板 |
| US10004883B2 (en) * | 2014-09-25 | 2018-06-26 | Intel Corporation | Contextual activation of pharmaceuticals through wearable devices |
| US11721414B2 (en) * | 2015-03-12 | 2023-08-08 | Walmart Apollo, Llc | Importing structured prescription records from a prescription label on a medication package |
| WO2016147276A1 (ja) * | 2015-03-13 | 2016-09-22 | 株式会社Ｕｂｉｃ | データ分析システム及びデータ分析方法並びにデータ分析プログラム |
| US10653622B1 (en) * | 2015-04-13 | 2020-05-19 | Pharmacoustics Technologies LLC | Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof |
| AU2016308953B2 (en) * | 2015-08-20 | 2020-09-10 | Glytec, Llc | Diabetes management therapy advisor |
| CA3006951C (en) | 2015-12-04 | 2024-05-14 | Icu Medical, Inc. | Systems, methods, and components for transferring medical fluids |
| KR20170074000A (ko) | 2015-12-21 | 2017-06-29 | 삼성전자주식회사 | 전자 장치 및 수면 관리 방법 |
| US11183276B2 (en) | 2015-12-22 | 2021-11-23 | International Business Machines Corporation | Medication dispenser system with exact personal dosing |
| AU2017208170B2 (en) * | 2016-01-11 | 2022-01-20 | Syqe Medical Ltd. | Method and system for controlling the delivery of active agents |
| US20190065802A1 (en) * | 2016-01-14 | 2019-02-28 | Aaron Hirschmann | Systems and Methods for Labeling, Identifying, and Tracking Data Related to Consumable Product |
| US20170220763A1 (en) * | 2016-01-28 | 2017-08-03 | Wal-Mart Stores, Inc. | System, method, and non-transitory computer-readable storage media for secure discrete communication with pharmacist of retail store |
| CN105825054B (zh) * | 2016-03-15 | 2018-01-09 | 北京千安哲信息技术有限公司 | 一种药物信息预测系统 |
| CN105975790A (zh) * | 2016-05-17 | 2016-09-28 | 南京航空航天大学 | 一种基于概率的个性化药物推荐方法 |
| EP3469359B1 (en) | 2016-06-14 | 2020-07-22 | Baze Labs AG | Personalised nutrient dosing with on-going feedback loop |
| CN106126889A (zh) * | 2016-06-15 | 2016-11-16 | 华南师范大学 | 基于知识库的药物定制方法和系统 |
| JP6791664B2 (ja) * | 2016-06-30 | 2020-11-25 | キヤノンメディカルシステムズ株式会社 | 造影剤管理装置 |
| USD851745S1 (en) | 2016-07-19 | 2019-06-18 | Icu Medical, Inc. | Medical fluid transfer system |
| JP7046051B2 (ja) | 2016-07-25 | 2022-04-01 | アイシーユー・メディカル・インコーポレーテッド | 医療用流体移送モジュールおよびシステムの中の空気バブルをトラップするためのシステムおよびコンポーネント |
| CN106202572B (zh) * | 2016-08-18 | 2020-03-06 | 广州视睿电子科技有限公司 | 电子书目录显示方法及装置 |
| CN207908510U (zh) * | 2016-09-21 | 2018-09-25 | 维布兰特公司 | 安装在抽水马桶上的传感器 |
| US11504024B2 (en) | 2018-03-30 | 2022-11-22 | Vibrant Ltd. | Gastrointestinal treatment system including a vibrating capsule, and method of use thereof |
| GB2554354B (en) | 2016-09-21 | 2021-06-02 | Vibrant Ltd | Systems for adaptive treatment of disorders in the gastrointestinal tract |
| US10482292B2 (en) | 2016-10-03 | 2019-11-19 | Gary L. Sharpe | RFID scanning device |
| US10692316B2 (en) | 2016-10-03 | 2020-06-23 | Gary L. Sharpe | RFID scanning device |
| US10249389B2 (en) * | 2017-05-12 | 2019-04-02 | The Regents Of The University Of Michigan | Individual and cohort pharmacological phenotype prediction platform |
| CN107256330A (zh) * | 2017-05-22 | 2017-10-17 | 深圳市见康云科技有限公司 | 一种运动方案的推荐方法、装置及计算机可读存储介质 |
| WO2018216015A1 (en) * | 2017-05-23 | 2018-11-29 | Kwik Commerce Ltd | System and method for automated supervision of consumption and inventory of appliance consumables |
| WO2019016788A1 (en) * | 2017-07-20 | 2019-01-24 | Eckstein Eitan Nathan | METHOD FOR DETERMINING A DHEA INTENSITY DOSE FOR A SPECIFIC PATIENT |
| US20190088354A1 (en) | 2017-09-01 | 2019-03-21 | Kit Check, Inc. | Identifying discrepancies between events from disparate systems |
| US20220008493A1 (en) * | 2017-09-01 | 2022-01-13 | Byrn Brands, LLC | Method for increasing thc/cbd content in a cannabis product |
| US11247032B1 (en) | 2017-09-07 | 2022-02-15 | Massachusetts Mutual Life Insurance Company | Wearable band for transdermal drug delivery |
| US20200323735A1 (en) * | 2017-10-25 | 2020-10-15 | Hewlett-Packard Development Company, L.P. | Release module group determination for delivery of a drug |
| US20190133886A1 (en) * | 2017-11-09 | 2019-05-09 | Kristine Brecht | System and method for dispensing medication |
| JP7106195B2 (ja) * | 2017-12-27 | 2022-07-26 | 株式会社オプティム | コンピュータシステム、薬提案方法及びプログラム |
| US11227692B2 (en) * | 2017-12-28 | 2022-01-18 | International Business Machines Corporation | Neuron model simulation |
| WO2019140432A1 (en) | 2018-01-15 | 2019-07-18 | Hygieia Health Co., Limited | Systems, methods, compositions and devices for personalized nutrition formulation and delivery system |
| US20190259482A1 (en) * | 2018-02-20 | 2019-08-22 | Mediedu Oy | System and method of determining a prescription for a patient |
| WO2019170180A1 (de) * | 2018-03-07 | 2019-09-12 | Ds-Technology Gmbh | Vorrichtung zum dosierten befüllen eines behältnisses mit einem füllgut |
| US11638678B1 (en) | 2018-04-09 | 2023-05-02 | Vibrant Ltd. | Vibrating capsule system and treatment method |
| US12083303B2 (en) | 2019-01-21 | 2024-09-10 | Vibrant Ltd. | Device and method for delivering a flowable ingestible medicament into the gastrointestinal tract of a user |
| US11510590B1 (en) | 2018-05-07 | 2022-11-29 | Vibrant Ltd. | Methods and systems for treating gastrointestinal disorders |
| AU2019288476A1 (en) | 2018-06-21 | 2021-03-18 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| US11093883B2 (en) * | 2018-08-03 | 2021-08-17 | Camelot Uk Bidco Limited | Apparatus, method, and computer-readable medium for determining a drug for manufacture |
| US11894109B1 (en) | 2018-10-15 | 2024-02-06 | Nantcell, Inc. | Production and delivery tracking and sample verification of patient-specific therapeutics |
| US12324857B2 (en) | 2018-11-29 | 2025-06-10 | R.P. Scherer Technologies, Llc | Apparatus and process for secondary encapsulation of solid inclusions using the rotary die process |
| US11779739B2 (en) * | 2018-12-21 | 2023-10-10 | Perfect Ip, Llc | Drug delivery system and method |
| CN113272001B (zh) | 2019-01-03 | 2024-04-05 | 维布兰特公司 | 用于将可摄入药物递送至使用者的胃肠道中的装置和方法 |
| CN109754858B (zh) * | 2019-01-11 | 2021-09-21 | 余鹏 | 甲氨蝶呤给药方案确定装置、存储介质及设备 |
| SG11202107994TA (en) * | 2019-01-23 | 2021-08-30 | Univ Michigan Regents | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
| EP3956903A4 (en) | 2019-04-17 | 2023-01-11 | ICU Medical, Inc. | SYSTEM FOR ON-BOARD ELECTRONIC CODING OF THE CONTENTS AND ADMINISTRATION PARAMETERS OF IV CONTAINERS AND THEIR SAFE USE AND DISPOSAL |
| EP3966828A1 (en) * | 2019-05-07 | 2022-03-16 | Medtronic, Inc. | Adaptive treatment management system |
| US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
| US11801423B2 (en) | 2019-05-10 | 2023-10-31 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to interact with a user of an exercise device during an exercise session |
| EP3975974A1 (en) * | 2019-05-24 | 2022-04-06 | Botanical Resource Holdings Proprietary Limited | A medicine compounding system |
| CN112071388A (zh) * | 2019-06-10 | 2020-12-11 | 郑州大学第一附属医院 | 一种基于深度学习的智能配药制药方法 |
| US10515715B1 (en) | 2019-06-25 | 2019-12-24 | Colgate-Palmolive Company | Systems and methods for evaluating compositions |
| US11551797B2 (en) | 2019-08-06 | 2023-01-10 | Kit Check, Inc. | Selective distribution of pharmacy item data from pharmacy item tracking system |
| US11915811B2 (en) * | 2019-09-03 | 2024-02-27 | Kaival Labs, Inc. | System and method for determining an appropriate dose of a product |
| US12402804B2 (en) | 2019-09-17 | 2025-09-02 | Rom Technologies, Inc. | Wearable device for coupling to a user, and measuring and monitoring user activity |
| CA3155575A1 (en) * | 2019-09-25 | 2021-04-01 | Janssen Pharmaceuticals, Inc. | Drug administration devices that communicate with external systems and/or other devices |
| US12469587B2 (en) | 2019-10-03 | 2025-11-11 | Rom Technologies, Inc. | Systems and methods for assigning healthcare professionals to remotely monitor users performing treatment plans on electromechanical machines |
| US11270795B2 (en) | 2019-10-03 | 2022-03-08 | Rom Technologies, Inc. | Method and system for enabling physician-smart virtual conference rooms for use in a telehealth context |
| US12176089B2 (en) | 2019-10-03 | 2024-12-24 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine for cardio-oncologic rehabilitation via an electromechanical machine |
| US11265234B2 (en) | 2019-10-03 | 2022-03-01 | Rom Technologies, Inc. | System and method for transmitting data and ordering asynchronous data |
| US12478837B2 (en) | 2019-10-03 | 2025-11-25 | Rom Technologies, Inc. | Method and system for monitoring actual patient treatment progress using sensor data |
| US12220201B2 (en) | 2019-10-03 | 2025-02-11 | Rom Technologies, Inc. | Remote examination through augmented reality |
| US20230245750A1 (en) | 2019-10-03 | 2023-08-03 | Rom Technologies, Inc. | Systems and methods for using elliptical machine to perform cardiovascular rehabilitation |
| US12347543B2 (en) | 2019-10-03 | 2025-07-01 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence to implement a cardio protocol via a relay-based system |
| US12230381B2 (en) | 2019-10-03 | 2025-02-18 | Rom Technologies, Inc. | System and method for an enhanced healthcare professional user interface displaying measurement information for a plurality of users |
| US12420143B1 (en) | 2019-10-03 | 2025-09-23 | Rom Technologies, Inc. | System and method for enabling residentially-based cardiac rehabilitation by using an electromechanical machine and educational content to mitigate risk factors and optimize user behavior |
| US11087865B2 (en) | 2019-10-03 | 2021-08-10 | Rom Technologies, Inc. | System and method for use of treatment device to reduce pain medication dependency |
| US20210134412A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | System and method for processing medical claims using biometric signatures |
| US12191018B2 (en) | 2019-10-03 | 2025-01-07 | Rom Technologies, Inc. | System and method for using artificial intelligence in telemedicine-enabled hardware to optimize rehabilitative routines capable of enabling remote rehabilitative compliance |
| US11282599B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouragement of rehabilitative compliance through patient-based virtual shared sessions |
| US12230382B2 (en) | 2019-10-03 | 2025-02-18 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to predict a probability of an undesired medical event occurring during a treatment plan |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US12327623B2 (en) | 2019-10-03 | 2025-06-10 | Rom Technologies, Inc. | System and method for processing medical claims |
| US12154672B2 (en) | 2019-10-03 | 2024-11-26 | Rom Technologies, Inc. | Method and system for implementing dynamic treatment environments based on patient information |
| US12427376B2 (en) | 2019-10-03 | 2025-09-30 | Rom Technologies, Inc. | Systems and methods for an artificial intelligence engine to optimize a peak performance |
| US12380984B2 (en) | 2019-10-03 | 2025-08-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to generate treatment plans having dynamically tailored cardiac protocols for users to manage a state of an electromechanical machine |
| US12246222B2 (en) | 2019-10-03 | 2025-03-11 | Rom Technologies, Inc. | Method and system for using artificial intelligence to assign patients to cohorts and dynamically controlling a treatment apparatus based on the assignment during an adaptive telemedical session |
| US11282608B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in or near real-time during a telemedicine session |
| US11139060B2 (en) | 2019-10-03 | 2021-10-05 | Rom Technologies, Inc. | Method and system for creating an immersive enhanced reality-driven exercise experience for a user |
| US12420145B2 (en) | 2019-10-03 | 2025-09-23 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning for generating alignment plans to align a user with an imaging sensor during a treatment session |
| US11955221B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US12224052B2 (en) | 2019-10-03 | 2025-02-11 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine for long-term care via an electromechanical machine |
| US11282604B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | Method and system for use of telemedicine-enabled rehabilitative equipment for prediction of secondary disease |
| US12150792B2 (en) | 2019-10-03 | 2024-11-26 | Rom Technologies, Inc. | Augmented reality placement of goniometer or other sensors |
| US11515021B2 (en) | 2019-10-03 | 2022-11-29 | Rom Technologies, Inc. | Method and system to analytically optimize telehealth practice-based billing processes and revenue while enabling regulatory compliance |
| US11826613B2 (en) | 2019-10-21 | 2023-11-28 | Rom Technologies, Inc. | Persuasive motivation for orthopedic treatment |
| US12424319B2 (en) | 2019-11-06 | 2025-09-23 | Rom Technologies, Inc. | System for remote treatment utilizing privacy controls |
| US20210137791A1 (en) * | 2019-11-11 | 2021-05-13 | Joey R. Gonzales | Capsule filler |
| CN110934584A (zh) * | 2019-12-09 | 2020-03-31 | 太原工业学院 | 一种生物数据测量装置 |
| EP3835803B1 (en) * | 2019-12-13 | 2024-03-27 | Siemens Healthineers AG | System and method for estimating a relative substance composition of a portion of a body of a patient |
| US11590057B2 (en) | 2020-04-03 | 2023-02-28 | Icu Medical, Inc. | Systems, methods, and components for transferring medical fluids |
| EP4128274A4 (en) * | 2020-05-22 | 2023-10-25 | Nokia Solutions and Networks Oy | DATA SOURCE, LOCATION AND ANALYSIS FOR PERSONAL DATA COLLECTED IN A PRIVATE CORPORATE NETWORK |
| JP6893052B1 (ja) * | 2020-06-29 | 2021-06-23 | ゲノム・ファーマケア株式会社 | 投与計画提案システム、方法およびプログラム |
| US12412660B2 (en) * | 2020-06-30 | 2025-09-09 | Fitzcarraldo Ab | Computer-implemented system and method for creating generative medicines for dementia |
| US12367960B2 (en) | 2020-09-15 | 2025-07-22 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
| US12136352B2 (en) * | 2020-11-30 | 2024-11-05 | Kpn Innovations, Llc. | System and method for initiating manufacturing of an edible combination |
| CN112712904B (zh) * | 2020-12-24 | 2023-10-27 | 四川省人民医院 | 基于嵌套-配对设计的多信息系统不良反应前置预测方法及系统 |
| KR102656669B1 (ko) * | 2020-12-30 | 2024-04-12 | 충북대학교병원 | 약물 부작용의 개인화된 확률을 산정하는 방법 및 장치 |
| EP4251116B1 (en) | 2020-12-31 | 2025-09-03 | Hero Health, Inc. | Sensing retrieval of pills |
| KR102285820B1 (ko) * | 2021-01-22 | 2021-08-03 | 박영철 | 유저의 의료 정보를 통한 의료용품 추천 및 판매 장치 |
| CN112802612B (zh) * | 2021-01-23 | 2023-10-31 | 广州医科大学附属脑科医院 | 基于精神分裂症的用药分析方法、装置、设备及存储介质 |
| US20220359057A1 (en) * | 2021-05-06 | 2022-11-10 | Noah Myers | Vitamin and Supplement System |
| TWI782608B (zh) * | 2021-06-02 | 2022-11-01 | 美商醫守科技股份有限公司 | 提供建議診斷的電子裝置和方法 |
| WO2022256038A1 (en) * | 2021-06-02 | 2022-12-08 | Aesop Technology Inc. | Method, apparatus related to medication list management, and computer-readable recording medium |
| US20230013530A1 (en) * | 2021-07-08 | 2023-01-19 | Rom Technologies, Inc. | System and method for using an ai engine to enforce dosage compliance by controlling a treatment apparatus |
| US11896555B2 (en) * | 2021-07-27 | 2024-02-13 | Chun Ching Lin | System and method for compounding error prevention |
| US12417834B2 (en) | 2021-07-30 | 2025-09-16 | Reviv Global Ltd | Genetically personalized intravenous and intramuscular nutrition therapy design systems and methods |
| US11894121B2 (en) | 2021-08-06 | 2024-02-06 | Reviv Global Ltd | Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods |
| US11600375B2 (en) | 2021-07-30 | 2023-03-07 | Reviv Global Ltd | Genetically personalized food recommendation systems and methods |
| DE102021132328A1 (de) | 2021-12-08 | 2023-06-15 | Syntegon Technology Gmbh | Pharmazeutische Produktionsanlage umfassend eine Messeinrichtung |
| EP4201390A1 (de) * | 2021-12-21 | 2023-06-28 | Harro Höfliger Verpackungsmaschinen GmbH | Kapselfüllmaschine zur befüllung zweiteiliger kapseln und verfahren zur befüllung zweiteiliger kapseln |
| US11941966B2 (en) | 2022-03-24 | 2024-03-26 | International Business Machines Corporation | Automatic determination and notification of irritant relief |
| US20230402144A1 (en) * | 2022-06-13 | 2023-12-14 | Mckesson Corporation | Methods and systems for predictive modeling |
| US20240257953A1 (en) * | 2023-01-27 | 2024-08-01 | International Business Machines Corporation | Distribution of surplus products using artificial intelligence |
| GB202311738D0 (en) * | 2023-07-31 | 2023-09-13 | Injenius Holdings Ltd | Nano scale intelligent conveyor & intelligent drug dispensary unit |
| CN117504062B (zh) * | 2023-11-11 | 2024-07-12 | 深圳医和家智慧医疗科技有限公司 | 一种自动计量定量给药的智能化雾化用药器的给药设备 |
| WO2025214546A1 (de) * | 2024-04-09 | 2025-10-16 | Schaeffler Technologies AG & Co. KG | Vorrichtung und verfahren zur herstellung eines pharmazeutischen erzeugnisses |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020042725A1 (en) * | 1994-10-28 | 2002-04-11 | Christian Mayaud | Computerized prescription system for gathering and presenting information relating to pharmaceuticals |
| US20060089856A1 (en) * | 2004-10-21 | 2006-04-27 | Cardiac Pacemakers | Integrated pharmaceutical dispensing and patient management monitoring |
| US20090171697A1 (en) * | 2005-11-29 | 2009-07-02 | Glauser Tracy A | Optimization and Individualization of Medication Selection and Dosing |
| CN101673362A (zh) * | 2008-09-08 | 2010-03-17 | 谢圣启 | 降低给药错误率的方法及其系统 |
| US20100100391A1 (en) * | 2005-11-14 | 2010-04-22 | Kantilal Kasan Daya | Pharmaceutical packaging and method for delivery of same |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
| US5084828A (en) | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
| US5992742A (en) * | 1994-08-05 | 1999-11-30 | Sullivan; Scott L. | Pill printing and identification |
| US5699649A (en) | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
| US5941380A (en) * | 1998-01-10 | 1999-08-24 | Rothman; David | Device for dispensing flowable material |
| US6219587B1 (en) * | 1998-05-27 | 2001-04-17 | Nextrx Corporation | Automated pharmaceutical management and dispensing system |
| US5960609A (en) | 1998-06-12 | 1999-10-05 | Microdose Technologies, Inc. | Metering and packaging method and device for pharmaceuticals and drugs |
| US6510430B1 (en) * | 1999-02-24 | 2003-01-21 | Acumins, Inc. | Diagnosis and interpretation methods and apparatus for a personal nutrition program |
| US6923979B2 (en) | 1999-04-27 | 2005-08-02 | Microdose Technologies, Inc. | Method for depositing particles onto a substrate using an alternating electric field |
| HN2000000165A (es) * | 1999-08-05 | 2001-07-09 | Dimensional Foods Corp | Productos holograficos comestibles, particularmente farmaceuticos, y metodos y aparatos para producirlos. |
| US6428809B1 (en) | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
| US6564121B1 (en) * | 1999-09-22 | 2003-05-13 | Telepharmacy Solutions, Inc. | Systems and methods for drug dispensing |
| US6658396B1 (en) | 1999-11-29 | 2003-12-02 | Tang Sharon S | Neural network drug dosage estimation |
| US6892941B2 (en) | 2000-06-08 | 2005-05-17 | Mendota Healthcare, Inc. | Automatic prescription drug dispenser |
| AU2002306629A1 (en) | 2001-03-02 | 2002-09-19 | Euro-Celtique, S.A. | Method and apparatus for compounding individualized dosage forms |
| EP1389083A2 (en) | 2001-05-15 | 2004-02-18 | E-Medication ApS | A medicine dispenser |
| US20070087048A1 (en) | 2001-05-31 | 2007-04-19 | Abrams Andrew L | Oral dosage combination pharmaceutical packaging |
| US20030010791A1 (en) * | 2001-07-13 | 2003-01-16 | Andrew Gentiluomo | Method and apparatus for dispensing a customized pharamaceutical mixture |
| US20040225527A1 (en) * | 2001-11-05 | 2004-11-11 | Holz Siegfried K. | Prescription fulfillment system and method |
| US7317967B2 (en) * | 2001-12-31 | 2008-01-08 | B. Braun Medical Inc. | Apparatus and method for transferring data to a pharmaceutical compounding system |
| CN100528255C (zh) | 2002-02-22 | 2009-08-19 | Gw药品有限公司 | 剂量分配系统和装置 |
| ATE394972T1 (de) * | 2002-12-04 | 2008-05-15 | Shobana Kamineni | Vorrichtung und verfahren zur sofortigen herstellung einer individuellen dosierungscharge |
| US8571881B2 (en) | 2004-11-09 | 2013-10-29 | Spectrum Dynamics, Llc | Radiopharmaceutical dispensing, administration, and imaging |
| CA2554251A1 (en) | 2004-02-02 | 2005-08-11 | Young-Kook Cho | Bottle cap |
| CA2577965C (en) | 2004-08-26 | 2014-07-29 | Christopher J. Colloca | Electromechanical adjusting instrument |
| JP2008510558A (ja) | 2004-08-27 | 2008-04-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 少なくとも１つの薬剤を投与する、電子制御され、遠隔制御されるピル及びシステム |
| WO2006028944A2 (en) | 2004-09-02 | 2006-03-16 | Simpson Edwin C | Pill dispensing apparatus |
| US7080755B2 (en) | 2004-09-13 | 2006-07-25 | Michael Handfield | Smart tray for dispensing medicaments |
| US8985388B2 (en) | 2004-12-11 | 2015-03-24 | Nitesh Ratnakar | Smart medicine container |
| US20070016443A1 (en) | 2005-07-13 | 2007-01-18 | Vitality, Inc. | Medication compliance systems, methods and devices with configurable and adaptable escalation engine |
| US12014328B2 (en) | 2005-07-13 | 2024-06-18 | Vccb Holdings, Inc. | Medicine bottle cap with electronic embedded curved display |
| ES2360605T3 (es) * | 2005-07-28 | 2011-06-07 | I.M.A. Industria Macchine Automatiche S.P.A. | Máquina para llenar cápsulas de movimiento intermitente. |
| EP1762512B1 (en) * | 2005-09-09 | 2008-07-30 | MG2 S.r.l. | Device for conveying capsules containing at least one pharmaceutical product |
| US20070122824A1 (en) * | 2005-09-09 | 2007-05-31 | Tucker Mark R | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime |
| AU2006304180A1 (en) * | 2005-10-14 | 2007-04-26 | Microdose Therapeutx, Inc. | Pharmaceutical packaging of an oral dosage combination |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| JP4679455B2 (ja) | 2006-07-13 | 2011-04-27 | 富士通株式会社 | 光増幅方法、光増幅器および光伝送システム |
| ATE553753T1 (de) * | 2007-02-16 | 2012-05-15 | Suisse Electronique Microtech | Überprüfungsverfahren |
| JP4058473B1 (ja) * | 2007-05-22 | 2008-03-12 | クオリティ株式会社 | 配合出力装置および配合出力プログラム |
| WO2009010884A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Tobacco-free oral flavor delivery pouch product |
| US8116907B2 (en) | 2007-11-29 | 2012-02-14 | The Invention Science Fund I, Llc | Reordering of consumable compositions |
| US7804419B2 (en) * | 2007-11-29 | 2010-09-28 | The Invention Science Fund 1, Llc | Programmed dispensing of consumable compositions |
| US20110146835A1 (en) * | 2008-08-23 | 2011-06-23 | Robert Terzini | Automated pharmacy drug handling and prescription verification system and method |
| US8284386B2 (en) * | 2008-11-26 | 2012-10-09 | Parata Systems, Llc | System and method for verifying the contents of a filled, capped pharmaceutical prescription |
| IT1392277B1 (it) * | 2008-12-18 | 2012-02-24 | Ima Spa | Macchina e metodo per riempire e controllare capsule |
| JP5263742B2 (ja) | 2009-01-26 | 2013-08-14 | 国立大学法人 筑波大学 | 服用者を見守る服薬確認システム |
| WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
| US20120189693A1 (en) * | 2009-06-25 | 2012-07-26 | Elite Laboratories, Inc. | Oral dosage forms |
| EP2603900B1 (en) | 2010-08-13 | 2024-04-24 | Intellimedicine, Inc. | System and methods for the production of personalized drug products |
-
2011
- 2011-08-15 EP EP11817178.4A patent/EP2603900B1/en active Active
- 2011-08-15 BR BR112013003331A patent/BR112013003331A2/pt not_active Application Discontinuation
- 2011-08-15 WO PCT/US2011/047809 patent/WO2012021899A2/en not_active Ceased
- 2011-08-15 MX MX2013001744A patent/MX2013001744A/es active IP Right Grant
- 2011-08-15 CN CN201910480856.6A patent/CN110391028A/zh active Pending
- 2011-08-15 CA CA2807949A patent/CA2807949C/en active Active
- 2011-08-15 US US13/210,333 patent/US10189616B2/en active Active
- 2011-08-15 AU AU2011289158A patent/AU2011289158B2/en active Active
- 2011-08-15 JP JP2013524264A patent/JP2013535756A/ja active Pending
- 2011-08-15 CN CN2011800491775A patent/CN103250176A/zh active Pending
-
2013
- 2013-02-12 IN IN290MUN2013 patent/IN2013MN00290A/en unknown
-
2016
- 2016-07-08 JP JP2016135871A patent/JP2017012761A/ja active Pending
-
2018
- 2018-08-28 JP JP2018159296A patent/JP6948994B2/ja active Active
-
2019
- 2019-01-28 US US16/259,785 patent/US11319125B2/en active Active
-
2022
- 2022-05-02 US US17/734,780 patent/US20220258935A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020042725A1 (en) * | 1994-10-28 | 2002-04-11 | Christian Mayaud | Computerized prescription system for gathering and presenting information relating to pharmaceuticals |
| US20060089856A1 (en) * | 2004-10-21 | 2006-04-27 | Cardiac Pacemakers | Integrated pharmaceutical dispensing and patient management monitoring |
| US20100100391A1 (en) * | 2005-11-14 | 2010-04-22 | Kantilal Kasan Daya | Pharmaceutical packaging and method for delivery of same |
| US20090171697A1 (en) * | 2005-11-29 | 2009-07-02 | Glauser Tracy A | Optimization and Individualization of Medication Selection and Dosing |
| CN101673362A (zh) * | 2008-09-08 | 2010-03-17 | 谢圣启 | 降低给药错误率的方法及其系统 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114981191A (zh) * | 2019-11-20 | 2022-08-30 | 雀巢产品有限公司 | 用于管理食物过敏口服免疫疗法药物的分发和治疗的方法和系统 |
| CN111326228A (zh) * | 2020-02-19 | 2020-06-23 | 清华大学 | 一种用于确定药物颗粒下呼吸道给药剂量的方法及系统 |
| CN111326228B (zh) * | 2020-02-19 | 2020-10-30 | 清华大学 | 一种用于确定药物颗粒下呼吸道给药剂量的方法及系统 |
| CN114582457A (zh) * | 2020-11-30 | 2022-06-03 | 国际商业机器公司 | 时间控制的药物 |
| TWI812056B (zh) * | 2022-03-10 | 2023-08-11 | 宏碁股份有限公司 | 檢查藥物相互作用的方法和電子裝置 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2807949A1 (en) | 2012-02-16 |
| US20190152663A1 (en) | 2019-05-23 |
| US11319125B2 (en) | 2022-05-03 |
| MX2013001744A (es) | 2013-06-28 |
| CN103250176A (zh) | 2013-08-14 |
| JP6948994B2 (ja) | 2021-10-13 |
| US10189616B2 (en) | 2019-01-29 |
| WO2012021899A3 (en) | 2012-05-10 |
| WO2012021899A2 (en) | 2012-02-16 |
| US20220258935A1 (en) | 2022-08-18 |
| BR112013003331A2 (pt) | 2017-07-11 |
| CA2807949C (en) | 2022-10-25 |
| JP2017012761A (ja) | 2017-01-19 |
| JP2019000677A (ja) | 2019-01-10 |
| EP2603900B1 (en) | 2024-04-24 |
| IN2013MN00290A (enExample) | 2015-05-29 |
| JP2013535756A (ja) | 2013-09-12 |
| AU2011289158A1 (en) | 2013-03-07 |
| EP2603900A4 (en) | 2016-11-16 |
| AU2011289158B2 (en) | 2014-09-04 |
| US20120041778A1 (en) | 2012-02-16 |
| EP2603900A2 (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220258935A1 (en) | System and methods for the production of personalized drug products | |
| JP3214893U (ja) | 携帯型薬剤ディスペンサー | |
| US20200303052A1 (en) | Therapeutic Hub | |
| US10494165B2 (en) | Medication event monitoring system | |
| JP2013535756A5 (enExample) | ||
| CA2768316A1 (en) | Pharmaceutical packaging and method for delivery of same | |
| KR20140018439A (ko) | 환자 주문형 치료법 | |
| US11594306B2 (en) | System and method for increasing medical adherence | |
| US20250014743A1 (en) | Therapeutic hub | |
| KR20250107856A (ko) | 약제 및 약제 사용량을 캡처하기 위한 시스템, 방법, 매체, 및 장치 | |
| US20220280391A1 (en) | Medication dispensing machine and system | |
| WO2022132205A1 (en) | System and method for blockchain based digital therapeutic devices to predict food-drug constituent interaction | |
| Fathillah et al. | Medication adherence manager and its clinical application. | |
| Haberer | Medication event monitoring systems | |
| Nehaa et al. | Spatially Variant based on Patch Division for Digital Pill Analysis Using Prototype Model | |
| Gunn | The Digital Pill–Crossing Boundaries? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191029 |